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1. Introduction 
Cardiovascular disease is the leading cause of death in most Western societies and it is 
increasing steadily in many developing countries. Aortic diseases constitute an emerging 
share of the burden. New diagnostic imaging modalities, longer life expectancy in 
general, longer exposure to elevated blood pressure, and the proliferation of modern non-
invasive imaging modalities have all contributed to the growing awareness of acute and 
chronic aortic syndromes. Despite recent progress in recognition of both the 
epidemiological problem, diagnostic and therapeutic advances, the cardiology community 
and the medical community in general are far from comfortable in understanding the 
spectrum of aortic syndromes and defining an optimal pathway to manage aortic 
diseases.  
Aortic aneurysms and dissections are the main disorders that can affect this artery in 
the thoracic cavity. Thoracic aortic aneurysms are usually asymptomatic, a silent 
disease, and they may not be diagnosed until a serious complication appears, such as 
acute aortic dissection or rupture. Those complications have a high morbidity and 
mortality, and entail a considerable healthcare expenditure. Prophylactic aortic surgery 
is being applied to prevent these potentially catastrophic aortic complications. It is very 
important to correctly identify patients at high risk, by establishing periodic monitoring 
and follow-up with imaging tests to determine the size of the aorta and the rate of aortic 
growth. 
There have been identified many genetic syndromes that may predispose to the 
development of thoracic aortic aneurysms and type A aortic dissections.  The most 
important is the Marfan syndrome, as almost all patients with this syndrome will develop 
an ascending aortic aneurysm throughout his life.  
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2. Body 
The Marfan syndrome (MFS) is an autosomal dominantly inherited disorder of connective 
tissue with multisystem involvement. It is caused by mutations in the FBN1 gene on 
chromosome 15, which encodes a glycoprotein called fibrillin-1, a component of the 
extracellular matrix. Over 1700 mutations have been identified in the fibrillin-1 gene 
associated with MFS, other genes related with the disease have been discovered and other 
disease-related genes with phenotypes very similar to this clinical syndrome (which need a 
thorough differential diagnosis) have been also identified. Because connective tissue is 
found throughout the body, MS can affect many body systems, including the ocular, 
cardiovascular, skeletal, and pulmonary Systems, as well as the skin and dura mater. The 
most serious signs and symptoms associated with MS involve the cardiovascular system; the 
cardiac complications, particularly aortic dilatation, dissection and rupture and involvement 
of the aortic and mitral valves, lead to a greatly reduced life expectancy.  
2.1. Diagnostic criteria for Marfan´s syndrome  
The MFS was described by the first time in 1896 by Antoine-Bernard Marfan, and it was not 
until 1995 that it was included in the connective tissue diseases classification. In 1986 a 
group of experts established a set of clinical criteria for the diagnosis of MFS (Berlin 
nosology). Later, in 1996 [1], it suffered a modification, known as Ghent's nosology (table 1), 
in order to avoid the overdiagnosis and to facilitate the differentiation with other similar 
syndromes. These criteria have been used throughout the world for the diagnosis of the SM, 
with a high specificity, as mutations in the gene FBN1 had been detected in up to 97 % of the 
patients who assemble these criteria [2]. Nevertheless, it presents some limitations, such as 
not consider the dependence on the age for some clinical manifestations, preventing the 
diagnosis in children, or to include not specific clinical manifestations, or with a poorly 
established diagnostic value. These facts may involve the overdiagnosis of MFS in patients 
with ectopia lentis or mitral valve prolapse syndrome; or on the contrary they may restrict 
the diagnosis in patients with ectopia lentis and aortic dilatation without sufficient skeletal 
manifestations.  
 
Organ / System 
Requirements for the classification of 
major criteria 
Requirements for the 
affectation of organs/systems 
Skeletal 
At least four of the following ones: 
1. Pectus carinatum 
2. Pectus excavatum that needs 
surgery 
3. Reduced upper segment / lower 
segment ratio, or increased armspan / 
height 
4. Thumb and wrist´s signs 
5. Curvature of the spine (20◦) o 
At least two findings for major 
criteria, or one of those and 
two of the following minor 
criteria: 
1. Moderate severity pectus 
excavatum 
2. Articular hypermobility 
3. Marked arch palate, or 
dental agglomeration 
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espondilolistesis 
6. Reduced elbow extension (<170◦) 
7. Medial displacement of the 
internal ankle causing plain flat feet 
8. Protrucio acetabulae 
4. Typical facial appearance 
(dolichocephaly, malar 
hypoplasia, retrognathia, 
downward slanting palpebral 
fissures, enophthalmos) 
Ocular Ectopia lentis 
Al least two of the following 
minor criteria: 
1. Flattened cornea 
2. Increase of the axial lenght 
of the eyeball 
3. Miosis reduced by iris of 
ciliary muscle hipoplasy 
Cardiovascular 
Al least one of the following ones: 
1. Ascending aortic dilatation, with 
or without regurgitation, concerning 
Valsalva sinus 
2. Ascending aortic dissection 
At least one of the following 
minor criteria: 
1. Mitral valve prolapse, with 
or without regurgitation 
2. Pulmonary artery dilatation, 
in absence of estenosis or other 
cause in adults < 40 years 
3. Mitral ring calcification in 
adults < 40 years 
4. Aortic dilatation or 
dissection 
Pulmonary None 
At least one of the following 
minor criteria: 
1. Spontaneous pneumothorax 
2. Apical bullous 
Coverings None 
At least one of the following 
minor criteria: 
1. Skin striae not associated 
with marked weight changes, 
pregnancy or repeated stress 
2. Recurrent of iincisional 
hernia 
Dura mater Lumbosacral dural ectasia None 
For the diagnosis of Marfan´s syndrome in patients without family history of the disease, there 
must be involved two organs / systems that assemble major criteria, and at least the affectation 
of a third organ / system. In patients with positive family history of this sybndrome, it is 
needed a major criteria, with information that suggest the affectation of a second system. 
Table 1. Diagnostic criteria of Ghent´s nosology 
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In order to solve the limitations of Ghent's nosology, it has been proposed a review  
of this. A group of international experts in the diagnosis and the management of  
MFS summoned in Brussels by the National Marfan Foundation, published recently 
“The revised Ghent nosology” [3], based on the review of wide cohorts of patients,  
experts opinion and the available literature about the application of the classic  
criteria, the differential diagnosis of the MS and the solidity and limitations of the 
genetic study. 
Among the most importants changes, a major value is granted for two cardinal findings of 
the MFS, the aneurysm/dissection of the root of the aorta and the ectopia lentis, being 
sufficient the combination of both to establish the diagnosis. The rest of ocular and 
cardiovascular manifestations, as well as the findings of other organs/systems, contribute to 
a systemic score that facilitates the diagnosis when the aortic disease is present but not the 
ectopia lentis (table 2).  
A more relevant role is assigned to the genetic study of the gene FBN1 and other related 
genes (TGFBR1 and TGFBR2). Some of the less specific manifestations lose importance in 
the diagnostic evaluation. 
The new criteria emphasize the need of diagnostic considerations and additional tests if 
patients assemble  sufficient criteria for MS but show unexpected findings, especially 
because of the possibility of an alternative specific diagnosis. It is emphasized specially in 
Sphrintzen-Goldberg and of Loeys-Dietz syndromes, and in the vascular form of Ehlers-
Danlos's syndrome. 
The new diagnostic criteria have been defined for a sporadic index patients, or for a patient 
with positive family history (table 3). 
 In absence of any family history, the diagnosis can be established in the following 
cases: 
1. The presence of aortic root dilatation or dissection (Z score ≥2, adjusted to age and body 
surface area) and ectopia lentis establish the diagnosis, independently of the presence of 
other systemic findings, except when these are indicative of other genetic syndromes of 
aortic aneurysm, as Sphrintzen-Goldberg and of Loeys-Dietz syndromes, and the 
vascular form of Ehlers-Danlos's syndrome 
2. The presence of dilatation or dissection (Z-score ≥2) and the identification of a mutation 
of the FBN1 gene is sufficient to establish the diagnosis of the MS. 
3. In presence of dilatation or dissection (Z-score ≥2) without ectopia lentis and ignorance 
of mutations of the FBN1 gene, diagnosis can be established when sufficient systemic 
findings exist (≥ 7 points); in this case, there must be excluded the possibility of other 
genetic aortic aneurisma syndromes. 
4. In presence of ectopia lentis without aortic dilatation / dissection, the identification of 
mutations of the FBN1 gene associated with aortic disease allows the diagnosis of the 
MS. 
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Wrist AND thumb sign: 3 (wrist OR thumb sign: 1) 
Pectus carinatum deformity: 2 (pectus excavatum o chest asymmetry: 1) 
Hindfoot deformity: 2 (plain flat foot: 1) 
Pneumothorax: 2 
Dural ectasia: 2 
Protrusio acetabulae: 2 
Reduced upper segment/lower segment and increased armspan/height: 1 
Scoliosis of thoracolumbar kyphosis: 1 
Reduced elbow extension 1 
3 of 5 facial features: 1 (dolichocephaly, enophthalmos, downward slanting palpebral 
fissures, malar hypoplasia, retrognathia) 
Skin striae: 1 
Myopia >3 diopters: 1 
Mitral valve prolapse: 1 
Maximum total 20 points; score ≥7 indicates systemic affectation.  
Table 2. Systemic findings score 
 In the presence of family history, the diagnosis can be established in the presence of 
ectopia lentis plus a systemic score ≥ 7 points, or the presence of aortic dilatation (Z ≥2 
in adults ≥20 years, or Z ≥3 in individuals <20 years). 
 
In absence of family history for Marfan´s syndrome
1. Ao (Z ≥2) and EL = MFSa 
2. Ao (Z ≥2) and FBN1 mutation = SMF 
3. Ao (Z ≥2) and systemic score  (≥7 points) = SMFa 
4. EL and FBN1 mutation identified in individuals with aortic aneurysm = SMF 
 EL with or withour systemic score, without FBN1 mutation, or with FBN1 mutation 
not related to aortic aneurysm/dissection = ELS 
 Ao (Z ≥2) and systemic score (≥5 points) without EL = MASS 
 PVM and Ao (Z <2) and systemic score (<5 points) without EL = SPVM 
In the presence of family history 
5. EL and FH of MFS = MFS 
6. Systemic score  ≥7 points and FH of MFS = SMFa 
7. Ao (Z ≥2 in > 20 years, Z ≥3 in < 20 years) and FH of MFS = MFSa
Ao: aortic diameter in Valsalva sinus (indicated by Z-score) or dissection; FBN1 mutation: 
mutation in fibrillin 1 gene; EL: ectopia lentis; MASS: phenotype with myopia, mitral 
valve prolapse, bordering expansion of aortic root (Z<2), skin striae and skeletal findings; 
PVM: mitral valve prolapse; ELS: ectopia lentis syndrome; MFS: Marfan´s syndrome; 
VMPS: mitral valve prolapse syndrome; Z: Z-score. 
a Warning: reject Shprintzen-Goldberg, Loeys-Dietz o vascular type Ehlers-Danlos 
syndromes, study of TGFBR1/2, COL3A1 mutations, and collagen biochemistry. 
Table 3. The revised Ghent nosology for the Marfan Syndrome 
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In addition, there are considered two new situations in patients younger than 20-year-old. 
The first of them, the “unspecific disorder of the connective tissue” for the cases with 
insufficient systemic findings (<7 points) and/or bordering dimensions of the aortic root (Z 
<3), without mutation of the FBN1 gene. The second one, the “MFS potential” for the 
sporadic or family history cases with mutation of the FBN1 gene and aortic dimensions with 
Z<3 score. 
In adults, three alternatives categories are defined: ecopia lentis syndrome (ELS), mitral 
valve prolapse syndrome (MVPS) and the phenotype MASS. 
Finally, the experts' panel recognizes the difficulty for establishing MFS's diagnosis in 
certain patients due to the overlapping phenotype of diverse entities. 
2.2. Hereditary syndromes related to thoracic aorta aneurysms 
The thoracic aortic aneurysms (TAA) are a relatively frequent entity, being responsible for 
approximately 15,000 annual deaths in USA. Up to 20 % of the patients with TAA, a genetic 
substratum is detected [4]. 
The familial TAA are classified in syndromics (they appear with phenotypics manifestations 
to other levels) and non syndromics (they appear as an isolated manifestation but with 
family aggregation, suggesting a genetic substratum). 
The MFS is the most important entity inside the familial syndromics TAA. It is necessary to 
establish the differential diagnosis between this one and others mixed connective tissue 
diseases with clinical manifestations and similar phenotypics features. The majority of these 
diseases (table 4) are monogenics and with a dominant autosomal inheritance. 
 
 
 
Familial Syndromic Thoracic 
Aortic Aneurysm Syndromes 
Non fibrilinopathies
Loeys-Dietz's syndrome 
Type IV Ehler-Danlos's syndrome  
Turner's syndrome 
Beals's syndrome 
Noonan's syndrome 
Alagille's syndrome 
Autosomal dominant polycystic kidney disease  
Fibrinilopathies 
Shprintzen-Goldberg's syndrome 
Weill-Marchesani's syndrome 
MASS phenotype 
Familial Non Syndromic 
Thoracic Aortic Aneurysm 
Syndromes 
TAAD1, TAAD2, TAAD3, TAAD4, TAAD5, FAA1 
and TAAD associated to ductus arterial persistent 
Bicuspid aortic valve 
Table 4. Differential diagnosis of Marfan's syndrome 
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Among the genetic syndromes that can be accompanied of TAA, we can emphasize: 
MAAS phenotype (mitral valve, aorta, skin, skeletal) 
It is included inside the fibrilinopathies group, that is to say, diseases results from mutations 
in the FBN1 gene. It is characterized by the presence of myopathy, mitral valve prolapse, 
aortic dilatation (slight and not progressive) and alterations of the cutaneous and 
musculoskeletal system. At least two systems must be affected. 
Loeys-Dietz's syndrome 
Autosomal dominant genetic syndrome caused by mutations in the genes encoding 
transforming growth factor β1 (TGFBR1) or 2 (TGFBR2). Two phenotypic variants can be 
currently distinguished (table 5). 
The aortic aneurysms are very frequent, appearing in 98 % of the cases, at early ages, and 
they are characterized by a high risk of dissection and / or rupture, even with diameters <5 
cm. Up to 53 % of the patients may develop aneurysms in other locations. In general way, it 
is accepted that those patients with more severe craniofacial manifestations present the most 
aggressive vascular disease. 
Patients with this syndrome are recommended to realize a complete imaging study to 
evaluate the aorta in the moment of the diagnosis and every 6 months, to check the growth 
rate of the TAA. An annual craniothoracoabdominal magnetic resonance must be fullfilled 
for the detection of systemics vascular aneurysms.  
 
 Type I Loeys-Dietz syndrome Type II Loeys-Dietz syndrome 
Phenotype Hypertelorism 
Craniosynostosis 
Cleft palate or bifid uvula 
Arterial tortuosity and 
aneurysms/dissections 
Without other craniofacial 
anomalies, except bifid uvula 
Similar to type IV Ehlers-Danlos's 
syndrome  
Mutated 
genes 
TGFBR1 and TGFBR2 TGFBR1 and TGFBR2 
Prevalence Unknown Unknown 
Prognosis 37 years of median survival 
Average age of death at 26 
years 
37 years of median survival 
Average age of death at 26 years 
Table 5. Variants of Loeys-Dietz's syndrome 
The surgical repair of the TAA in patients with Loeys-Dietz's syndrome must be realized 
when the internal diameter overcomes 4,2 cm for transesophageal echocardiogram or the 
external diameter is major than 4,5 cm in a computerized tomography or magnetic 
resonance. 
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Ehlers-Danlos's syndrome vascular type or type IV Ehlers-Danlon´s syndrome 
It is caused by mutations in the genes encoding the collagenous type 3 (COL3A1) with an 
autosomal dominant inheritance. It is characterized by vascular and visceral external 
fragility, which can lead to vascular and visceral spontaneous breaks or with minimal 
traumatisms. The cutaneous or articular hyperlaxity is less marked that in other subtypes. 
The majority of the deaths are due to vascular breaks. 
It is recommended to carry out non invasive imaging tests because of the high risk of 
vascular break. It is unknown the usefulness of the aortic surgery in the repair of the not 
complicated TAA. In case of dissection or rupture, the urgent surgery is indicated, with 
specially attention to the vascular anastomosis because of the trend to the hemorrhage, 
vascular fragility and the difficulties in the tissue regeneration capacitiy in this 
syndrome.   
Turner's syndrome 
It is a chromosomal abnormality in which the monosomy X is the most common (cariotipe 
45, X0). The patients affected with Turner's syndrome present characteristic physical 
abnormalities such as short stature, webbed necks and sterility. There can be associated 
differents cardiovascular manifestations, as the coarctation of aorta, early ischemic 
cardiopathy, bicuspid aortic valve and TAA (up to 40 % of the cases). The incidence of aortic 
dissection in these patients is greater compared with the healthy population, six-times 
increased risk, with a median age of presentation of 31 years. 
It is recommended to realize an initial imaging test to reject bicuspid aortic valve, 
coarctation of aorta and / or TAA. If the test is normal and there is no risk factors for aortic 
dissection it is enough to do an imaging test every 5-10 years. In the opposite case, annual 
controls are advised. Inthose patients with Turner´s syndrome who are planning the get 
pregnancy, an imaging test must be realized to determine the risk of aortic dissection. 
Autosomal dominant polycystic kidney disease  
Disease caused by a mutation in the genes PKD1 and PKD2. Its more frequent complication 
are the hemorrhages subaracnoideas due to the rupture of cerebral aneurysms. It is also 
associated with an increase in TAA and type-A aortic dissections.   
Beals's syndrome or congenital contractural arachnodactyly 
It is an autosomal dominantly inherited connective tissue disorder caused by a mutation in 
FBN2 gene. Although the clinical features can be similar to Marfan syndrome, multiple joint 
contractures (especially elbow, knee and finger joints), arachnodactyly, severe 
kyphoscoliosis, abnormal pinnae, muscular hypoplasia and crumpled ears in the absence of 
significant aortic root dilatation are characteristic of Beals syndrome and rarely found in 
Marfan syndrome.  
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Responsible gene Familiar Non 
syndromic TAA 
% Aortic dissection 
Unknown gene 
Locus 5q13-14 
Gene that codifies for the 
proteins versican, 
trombospondina 4 and 
protein related to the cartilage
TAAD1 
TGFBR2 
Gene that codifies the receptor 
of the transforming growth 
factor β2 
Mutation in  arginina 460, 
locus 3p24-25 
TAAD2 
The same gene 
mutated in the 
syndrome Loeys-Dietz 
5 % Risk of aortic dissection 
with diameter <5 cm 
Recommendations similar 
to those for Loeys-Dietz's 
syndrome 
MYH11 
Heavy chain of the 11-
βmiosina, specific for smooth 
muscle cells. 
Located in the chromosome 
16p 
TAAD-persistent 
arterious ductus 
1 % Risk of aortic dissection 
with diameter ≤4,5 cm 
ACTA2 
Gene that codifies for the 
region alfa2 of the actina of 
the aortic smooth muscle. 
Locus 10q22-24 
TAAD4 15 % Risk of type A aortic 
dissection with diameter 
<5,0 cm and at early ages 
of life 
Risk of type B aortic 
dissection with < 21 years 
old
TGFBR1 
Gene that codifies the receptor 
of the transforming growth 
factor β1 
Locus 9q33-34 
TAAD5 
The same gene 
mutated in Loeys-
Dietz's syndrome and 
Furlong's syndrome 
FAA1 
Locus 11q23-24 
FAA1
FBN1 
Gene that codifies the fibrilina 
1 
Locus 15q21.1 
It can present mosaicism in 
somatic and germinate cells 
The same gene 
mutated in 
Shprintzen-Goldberg's 
syndrome, Weill-
Marchesani's 
syndrome and the 
phenotype MASS 
(fibrilinopathies)
Table 6. Familial non syndromic thoracic aortic aneurysm syndromes (see text) 
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The majority of the familial TAA and aortic dissections are produced in patients who cannot 
be fitted in any of the syndromes described before. The studies of family aggregation 
suggest that between 11 and 19 % of the patients with TAA or dissections present a first 
degree relative with this antecedent. 
In general, the presentation of aoritc complications (rupture and/or dissection) in patients 
with familial non syndromics TAA occur at earlier ages in comparison with the sporadic 
aneurysms (median age of 56,8 years opposite to 64,3 years), though without reaching the 
precociousness of the syndromics TAA. The aortic dilatation can concern both the tubular 
portion of the ascending aorta and sinus of Valsalva. The age of appearance and the growth 
rate are very changeable, event inside the components of a same family.  
From a genetic point of view, the familial non syndromic TAA are very heterogeneous, 
having been located up to 7 different loci, that can explain only 20% of the cases: TAAD1, 
TAAD2, TAAD3, TAAD4, TAAD5, FAA1 and TAAD-partner to persistent arterial ductus 
(table 6). The way of inheritance is autosomal dominant with incomplete penetrance, minor 
in the female sex.    
In patients with familial non syndromic TAA it is necessary to realize an individualized 
genetic advine to the relatives. It is necessary to realize a genetic analysis to the first degree 
relatives in case of a known mutation in the index case. In the first degree relatives with a 
negative genetic study, it is recommended an unique imaging test to reject aortic pathology. 
In case of presenting any of the genetic mutations described mutations, periodic reviews 
must be made every 2 years approximately.  
2.3. Genetics of Marfan's syndrome 
Marfan syndrome results from mutations in the fibrillin-1 (FBN1) gene located on 
chromosome 15q21.1 and, occasionally, by mutations in TGFβR1 or TGFβR2 genes 
(transforming growth factor-β receptor 1 and 2) located on chromosome 9 and on 
chromosome 3p24.2-p25, respectively [5]. More than 500 fibrillin gene mutations have been 
identified. Almost all of these mutations are unique to an affected individual or family. 
Different fibrillin mutations are responsible for genetic heterogeneity. Phenotypic variability 
in the presence of the same fibrillin mutation suggests the importance of other, yet-to-be-
identified factors that affect the phenotype. 
Fibrillin-1 (FBN1) gene 
The fibrillin-1 gene consists of 65 exones and it is located in the chromosome 15q-21.1. It 
encodes for the glycoprotein fibrillin, which is a major building block of microfibrils that 
constitute the structural components of the suspensory ligament of the lens and serve as 
substrates for elastina in the aorta and other connective tissues.  
The FBN1 gene is characterized for having several rich sequences in cysteine, comparable to 
the factor of epidermal growth (EGF). 47 exones codify a complete domain EGF and 43 of 
these include the sequence consensus for the union to the calcium Asp/Asn-x-Asp/Asn-
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Glu/Gln-xm-Asp/Asn*-xn-Tyr/Phe (where x represents any amino acid, * it represents possible 
beta-hydroxylation of this residue and "m" y "n" represent a variable number of residues). 
Each of the EGF-similar contains six residues highly preserved of cysteine that form three 
disulfide bonds between C1 and C3, between C2 and C4 and between C5 and C6, resulting 
in a structure of βeta strand what is involved in the union to the calcium. Calcium plays a 
very important role in the stability of the domain and awards a major resistance to the 
proteolytic degradation. 
Nowadays, several strategies can be used in the genetic study of the FBN1 gene, being the 
reference the direct sequentiation of the exones and the border intron regions. Another 
method is the high-performance denaturing liquid chromatography liquid, with later 
confirmation for direct sequentiation. When a mutation is not identified and there is a high 
clinical suspicion of the presence of the disease, there can be looked big 
deletion/duplication, impossible to detect for the previous methods, using MLPA (multiplex 
ligation-dependent probe amplification). Finally, the analysis of genetic linkage can be used 
to determine if an individual has inherited an allele of the FBN1 gene that is associated with 
the syndrome in several members of the family, nevertheless its cost and efficiency are 
limited compared by the sequencing technique. 
In order to consider the identified mutation as responsible, the following criteria must be 
evaluated: 
1. If the mutation has been described before, familial consegregation must be 
demonstrated, that is to say, that in a family with MFS, the ones with the mutation must 
be affected and those without the mutation must be healthy. 
2. If the mutation has not been described before, it is necessary to consider the following 
premises: 
a. Certain mutations have a high probability of being pathogenic: 
- Nonsense mutation, that creates a premature stop codon 
- Insertion/deletion that concerns a number of bases that is not multiple of three, 
and consistently alters the reading, usually creating a premature stop codon 
- Mutation that affects the splicing of the sequence of reference or that alters to 
level of the cDNA/mRNA (“splice site mutations”); mechanism that forms a 
part of the mRNA maturation consisting of the elimination of the introns so 
that a codificant and without interruptions sequence is obtained, and it can be 
translated into protein. 
- Missense mutation that creates or replaces cysteine 
- Missense mutation that concerns a preserved residue of the consensus EGF 
sequence. 
b. The mutation must concern a preserved residue in the evolution. It is considered 
that the amino acids that have not suffered changes along the evolutionary scale 
are important for the function of the same one. 
c. For the demonstration of the pathogenic of a mutation, bioninformatic models can 
be used so that they can predict if the change that induces the mutation can carry 
deleterious effects or not in the protein. 
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d. The familial consegregation must be demonstrated if possible, and the absence of 
the mutation in at least 40 chromosomes of the same etnia, that is to say, at least in 
200 subjects. 
e. The pathogenicity is high probably in the identified mutations by genetic linkage. 
The sensibility to find a mutation in a patient with MFS is high, varying between 76 and 93% 
in recent studies. It depends on several factors, as the age, the familial history or the method 
used for the genetic study. 
Marfan syndrome is known as an autosomal dominant connective tissue disorder. Hereby, 
the risk that a son of an affected father has the disease is 50%. Approximately, 75% of the 
patients with MFS has one of his parents affected, and only in 25% the affected one presents 
a de novo mutation.     
The penetration of the mutations in FBN1 is in general high, being considered to be near to 
100%. It has been communicated exceptional cases of incomplete penetration. It is necessary 
to consider that many of the manifestations appear with the age. 
Those patients with severe and progressive forms of the disease (called “The neonatal 
Marfan Syndrome”) usually have mutations in the central part of the gene, between exons 
24 and 32 of FBN1. Affected individuals are generally diagnosed at birth or shortly 
thereafter. Congestive heart failure associated with mitral and tricuspid regurgitation is the 
main cause of death, whereas aortic diseection is uncommon; survival beyond 24 months is 
rare. As a general rule, the mutations that produce insertions or deletions with change or 
displacement of the frame of reading or splice site mutations, are usually associated to severer 
forms of the disease. The patients with mutations that alter the terminal-C-propeptide 
procesate have been related to predominantly skeletal affectations of the disease. It is 
evident that it is necessary to compile information about the clinical consequences and the 
phenotype associated with different mutations, since mutations with the same mechanism 
can have very different clinical consequences, as it is demonstrated in other genetic 
pathologies. 
The diagnosis of the MFS can be realized without needing a genetic study. Nevertheless, it 
has a great importance in the following suppositions: 
1. It is of great relevancy in patients who do not fulfill clinical criteria, especially in 
patients with ectopia lentis and patients with cardiovascular suggestive features 
combined with skeletal findings or in sporadic cases in young subjects. 
2. It is very useful in relatives of affected patients, especially children, to know if they 
have inherited the mutation of their parents and so they will need periodic controls. 
3. It must be realized in patients in whom the genetic diagnosis can influence their way of 
life, as in high competitive sports, for the initiation of the treatment or programming of 
clinical follow-up. 
4. It can be useful for prenatal diagnosis, analyzing DNA extracted from foetal cells 
obtained of the chorionic villus between 10 and 12 weeks´ gestation. It might be done 
whenever a causal mutation had been identified in the relative, with pathogenicity 
 
Marfan Syndrome – Advances in Diagnosis and Management 439 
clearly demonstrated, and avoiding the pollution by mother DNA of the studied 
sample, in the cases in which the mother is affected. 
5. In the preimplantational diagnosis in in-vitro fertilization treatments. The use for the 
prenatal and preimplantational diagnosis is controversial in many countries, with 
ethical and legal aspects that must be have in mind. 
Transforming growth factor-β receptor 1 and 2 (TGFBR 1 and 2) 
There have been found mutations in these genes in some of the MFS diagnosed patients or 
thos with MFS's suspicion. These patients present a more aggressive form of the vascular 
disease, with dissections and ruptures at earlier ages and with smaller diameters. Initially 
they were identified by MFS's type 2, leaving the type 1 for mutations in the FBN1 gene. 
Later, these patients with marfanoid phenotype, aggressive vascular disease and other 
morphologic features (hyperterolism, bifid uvula, …) were grouped in Loeys-Dietz's 
syndrome. Thus, we can find it with both nomenclatures. 
2.4. Use of biomarkers in Marfan's syndrome 
According to the definition of the National Intitutes of Health, a biomarker is “a 
characteristic that can be quantified and evaluated in an objective way as an indicator of 
normal biological processes, pathogenic processes or pharmacological answers to a 
therapeutic intervention” [6]. The employment of biomarkers facilitates the identification 
of patients at risk, and they are usually molecules that can be identified by a blood 
analysis.   
Nowadays we don´t have many specific bibliography about circulatory biomarkers for the 
thoracic aortic aneurysm. The not circulatory biomarker that is in use with more frequency 
is the diameter of the aneurysm.  
Below we will detail the biomarkers that could have importance in the clinical management 
of the thoracic aortic aneurysms, as in Marfan syndrome: 
D-dimer 
It has been demonstrated that the concentrations of D-dimer allow to detect the Stanford 
type A acute aortic dissection. The concentration of the D-dimer obtained during the 
hospital admission is correlated by the survival of these patients. Thus, elevations in the 
concentration of D-dimer in patients who come to Emergency Room for thoracic pain it 
should be realized a tomography computerized to reject acute aortic dissection as well as 
acute pulmonary embolism. 
Cellular biomarkers 
There have been identified two types of cells that are associated with the evolution of an 
aneurysm, the CD 28 T-lymphocytes and the natural citolytic lymphocytes or natural 
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killer. It has been demonstrated in studies the presence of population of natural killer 
lymphocytes in greater number in patients with abdominal aortic aneurysm compared 
with healthy subjects. The CD 28 T-lymphocytes appear in diverse inflammatory 
disorders, and express in a more frequent form with the age. It has been observed in 
patients with aneurysms greater quantity of this cellular type in peripheral blood 
compared to healthy controls. In addition, on a contradictory way, highest rates are found 
in patients with smaller aneurysms in comparison with patients with big aneurysms, 
appearing the hypothesis about the intervention of Cd 28 T-lymphocytes in the genesis of 
the aneurysms. 
Biomarkers in plasma and serum 
Several circulating biomarkers have been identified with the aneurysms, in relation to their 
appearance, diameter or expansion. These can be classify in inflammation biomarkers, 
indicators of tissue turnover, and others as homocysteine, serum amyloid A, osteopontin, 
osteoprotegerin and the concentrations of plasmin / antiplasmin complex. 
Inflammation biomarkers have been the more widely studied. At present, the formation of 
the aortic aneurysm is understood as an inflammatory process. Many studies relate diverse 
inflammatory cytokines (interleukin-1, interleukin-6, tumor necrosis factor-α, interferon γ 
and cold-reactive proteins) to the formation, expansion or rupture of the aneurysm. Its 
disadvantage is the lack of specificity, being able to rise their concentrations in other 
inflammatory processes, reason why their clinical utility as aortic aneurysm biomarker is 
limited. 
Special mention is deserved to the matrix metallooproteinases (MMPs). Their main 
function is the degradation of the extracelular matrix. The MMPs are active in many 
pathological processes, either in trivial ones as periodontitis or others more serious as heart 
failure. In experimental models with animals, there has been demonstrated that MMP's 
inhibition, by genetic deletion directed or by pharmacological intervention, determines a 
minor progression of the abdominal aortic aneurysms. In patients with abdominal aortic 
aneurysm, the circulating concentrations of MMP-9 presented a direct correlation with the 
concentrations of MMP-9 in the aortic wall. It has been observed an increase in the 
concentration of MMP-1 and MMP-9 in the thoracic aortic walls with aneurysms or 
dissections in comparison with healthy controls. It has also been observed an increase of 
the quotient MMP-9/TIMP-1 (tissue inhibitor of metalloproteinases-1), favoring the 
proteolysis of the aortic wall. Other studies have documented a correlation of MMP's 
activity, especially MMP-9, with the genesis and evolution of the thoracic aortic 
aneurysms. 
Molecular biomarkers 
It has been studied the RNA of circulating leukocytes and there have been identified 
characteristics of expression that relate to the appearance of thoracic aneurysms, with an 
accuracy up to 78%. In the same line, there has been identified a hyperexpression of certain 
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genes in patients with thoracic and abdominal aortic aneurysms. Among these genes, we 
must emphasize those who codify the intracellular adhesion molecule-1, v-yes-1 oncogene, 
mitogen activated protein kinase and the MMP-9. 
In short, it does not exist a perfect biomaker for a pathological process. In case of the 
thoracic aortic aneurysms, the best described biomarker and with wide diffusion in the 
clinical practice is the diameter of the same one. Big advances have been achieved in 
circulating biomarkers, though further study is required to be able to generalize it to the 
daily clinical practice.   
2.5. Diagnosis of the aortic affectation in the MFS 
In a summarized form, the management of the aortic pathology in the MFS is based on the 
clinical study and imaging techniques to detect and to quantify the progression of the aortic 
expansion [7]. 
The initial clinical evaluation of every patient with MFS's suspicion must include anamnesis 
and a complete clinical examination. The diagnosis of certainty can be reached in almost 
90% of the cases through the Ghent´s nosology, being able to be completed by the genetic 
study as we have described before. To complete the information about diagnostic criteria 
(table 1) we will carry out an imaging test that allows to evaluate the ascending aorta and 
the cardiac valves.  
The transthoracic echocardiogram (TTE) represents the main technique for the diagnosis 
of the cardiovascular affectation in the initial evaluation of patients with MFS, allowing to 
explore the aortic root, the proximal ascending aorta and the aortic arch. The maximum 
diameters of the aortic annulus, Valsalva sinus, sinotubular junction and of the ascending 
aorta must be measured perpendicularly to the longitudinal axis of the aorta. The 
obtained information will be compared in nomogramas with the expected values 
according to the age, the sex and the corporal surface. The severity of the aortic affectation 
relates to the degree and the extension of the dilatation, being most important when it 
spreads from the root over the ascending aorta up to the aortic arch. The second TTE will 
be carried out at 6 months of the diagnosis to determine the speed of growth. If the 
diameter remains stable, the ultrasonic study can be realized anually, but if accelerated 
expansion is detected or when it comes closer to 45mm, the evaluation will have to be 
more frequent (table 7). 
In spite of the fact that the transthoracic echocardiogram is the most used technique to 
monitor the size of the aortic root, its precision depends on the operator. The 
computerized tomography (CT) or the magnetic resonance (MRI) are more precise and 
must be used if the echocardiogram does not give a suitable image of the aorta. It is 
advisable to know that the echocardiographic measures, being realized between internal 
edges, can be up to 4mm lower than the obtained ones with MRI or CT, in which the 
thickness of the wall joins. 
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Anamnesis, physical examination, echocardiogram: 
At the beginning and at the 6 monthsa 
 Later: every year, if the growth rate is stable and without complicationsa 
CT or MRI: 
If there is aortic dilatation or dissection. 
After the surgery, before the discharge, at 6 months, and then anually. 
The evaluation will be more frequent as the aortic root approaches 45mm or if it is 
registered an accelerated rate of growth (> 5 mm / year) 
a Class I recommendation, level of evidence C. 
b It is consider of utility to correct the aortic diameters in accordance with the age and the 
corporal size (class IIa, level of evidence C). 
Table 7. Cardiovascular follow-up in Marfan's syndrome 
2.6. Pharmacological treatment in the prevention of the cardiovascular 
complications of the MFS 
The pharmacological treatment in the prevention of the cardiovascular pathology in patients 
with MFS is based on the employment of β-adrenergic blocking agents and renin-
angiotensin system antagonists [8].  
Beta blockers 
Many studies have demonstrated that the employment of betablockers can slow down the 
aortic rate expansion and delay the moment of appearance of the aortic complications of the 
MFS, as the aortic regurgitation, the aortic dissection, the need of surgery, the congestive 
heart failure or the death, specially if they are use in the initial phases of the disease, as they 
can reduce the hemodynamic stress of the thoracic aorta wall.  
These benefits are in all the groups of age, being more important in patients with not severe 
aortic dilatation. 
Nowadays the clinical guidelines recommend the employment of betablockers at the right 
dose in all patients with MFS who tolerate them, independently from the degree of aortic 
dilatation. 
Given that the aortic growth rate changes along the life, presenting a prepuberal peak,  
it is recommended the beginning of the treatment with betablockers in the infancy,  
and to support it forever, even in patients who have received aortic prophylactic  
surgery. 
The effects of the pharmacological treatment must have a periodic review to assure  
an optimal management of the cardiac frequency and the arterial pressure of the patient 
(table 8). 
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Betablockers Use always in MFS, except in cases of intolerancea 
Atenolol: more used (long half-life and cardioselective) 
Dose: to title up to CF at rest <60 lpm and <100 lpm in exercise, if the 
AP allows it. 
To monitor the efficiency and the doses in periodic visits 
Calcium 
channel 
blockers 
Verapamil: second line treatment in patients who do not tolerate 
betablockers 
ACE 
inhibitors 
Associated to betablockers when additional treatment is needed to 
control the AP, specially those with chronic dissection 
AT1R-II AT1 blockers (losartan) associated to betablockers; in small not randomized 
studies, major efficiency in delaying the aortic rate growthb. 
AT1 blockers, associated to betablockers; alternative use to ACEi when 
additional medication is needed for AP's control 
a Class I recommendation, level of evidence B.
b Class IIa recommendation, level of evidence B.
Table 8. Pharmacological treatment in the MFS 
Renin-angiotensin-aldosterone system antagonists 
The influence of the renin-angiotensin-aldosterone system in the aortic wall degeneration of 
the MFS seems to be increasingly important. The angiotensin II (ATII) stimulates the 
expression of metalloproteases and promotes the apoptosis of the smooth muscle cells in the 
aortic wall. The experimental models have demonstrated that the deficiency of FBN1 
increases the TGF-β active, causing the detention of the cellular differentiation cicle, an 
increase of the apoptosis and deposit of extracelular matrix. The employment of renin-
angiotensin system antagonists by means of angiotensin-converting-enzyme inhibitors 
(ECAs) or with angiotensin II receptor antagonists (ARAII), produces beneficial effects at 
different levels. The ECAs contribute, apart from the control of the AP, to the decrease of the 
inflexibility of the aortic wall. The selective block of the type 1 receptor (AT1) of the 
angiotensin II might reduce the deleterious effects of the TGF-β, independently of the effects 
on the control of the AP. Though in animal models, losartan has demonstrated to stop and 
even to revert MFS manifestations, including the aortic aneurysm and its complications, we 
are waiting for the results of controlled clinical trials in human beings that are in process. 
It is important to insist that the medical treatment, based fundamentally on betablockers, 
which is possible to associate to the renin-angiotensin system block, gets delaying the aortic 
expansion, but no medicament, up to the moment, has demonstrated either to avoid the 
development of aortic dissection or to avoid the need for surgery in human beings. 
Physical activity 
To reduce the hemodynamic stress in the MFS, the restriction of the physical activity 
complements the pharmacological therapy. The intense isometric exercise is contraindicated 
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due to the marked increases in the peripheral AP and the stress of the proximal aortic wall. 
Also competitive sports, contact sports and those that with marked changes in the atmospheric 
pressure are contraindicated, to prevent the arterial traumatism and the pneumothorax. Since 
the dynamic exercise is associated with minor aortic stress, for the decrease of the peripheral 
vascular resistance and of the diastolic AP, in patients without high risk, the practice of aerobic 
activity of moderate intensity is considered to be sure (table 9). 
2.7. Prophylactic surgery of the proximal aorta 
In the MFS, the prophylactic surgery of the aortic root and the ascending aorta is 
recommended, because of the high mortality of the emergency aortic replacement and 
because both, the type A aortic dissection and the aortic rupture, are the complications with 
major impact in the survival. Though technically more complex, the aortic valve 
conservation techniques, remodeling or reimplantation, are usually the ones preferred than 
the valvulated tubes, whenever they offer good results. 
Provided that the dissection and mortality risk are proportional to the size of the proximal 
aorta, the guidelines recommend elective surgery in adults when the external diameter is 
≥50mm. The surgery also must be considered in patients with diameter <50mm if they 
present additional risk factors: rapid growth of the aortic diameter (> 5mm/year), familial 
history of aortic dissection or rupture, or the presence of significant aortic regurgitation 
(table 10). 
With regard to the timing of the elective surgery, some considerations must be done. 
According to the value of the threshold of the diameter, a more or less important proportion 
of patients will present complications without reaching this value or will surrender 
unjustibiably to the surgical risk of an elective procedure still being removed from 
complications. It turns out important to incorporate another information, as the growth rate, 
and indexing the diameters by body surface. The corporal surface, used in many 
nomograms on having contemplated the weight, can artificially modify the surgical risk. 
The current trend is to correct according to the stature, in order that in subjects of minor 
stature, specially women, but at risk of complication, surgery could be indicated even if 
their diameters were more near to 45 that to 50mm. In the clinical practice, the surgical 
indication starts beeing considered when the aorta is expanded (≥2 deviations over the 
average, Z-score≥2) or when its diameter comes closer to 45mm (before if the stature is 
lower than 170cm). The surgical results are determinant to indicate prophylactic surgery, 
preferably preserving the valve and with very low mortality, necessarily lower than 5%. 
In children and teenagers with MFS, the establishment of a relation with the diameter of the 
aorta is more difficult than in adults, since the complications are infrequent before 12 years 
of age. The elective aortic surgery in this population, up to 18 years, is recommended when 
the aortic diameter exceeds 50mm, when there is a rapid aortic growth (> 10mm/year), when 
aortic regurgitation appears, or when there is simultaneous affectation of the mitral valve. 
As for the timing, it is necessary to weigh the risk of dissection and the delay of the surgical 
moment to avoid prosthetic mismatch, since the children will continue growing. The 
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paediatric nomograms have been re-calculated to improve their correspondence with those 
of adults. The normalization for sex, age and corporal surface seems to be suitable, though it 
will be necessary to define better which is the dilatation of risk in which the benefits of the 
prophylactic surgery unequivocally overcome the risks. 
 
Type of patient Recommendation 
Every patient with SM: Any degree of aortic root 
dilatation 
To avoid contact sports of contact 
and those with risk of corporal 
impact 
Low risk: all the following ones: 
Without aortic root dilatation: 
 Adults, root <40 mm 
 Children and teenagers: root Z-score <2 
Mitral regurgitation less that moderated 
Without familial history of dissection or sudden 
death 
Static and dynamic activity of low 
and moderate intensitya 
 
Risk: any of the following ones: 
Aortic root dilatation 
 Adults, root ≥40 mm 
 Children and teenagers: root Z-score ≥2 
Moderate or severe mitral regurgitation 
Previous surgery of aortic root 
Chronic dissection 
Familial history of dissection or sudden death 
Alone advisable dynamic activity of 
low intensity 
 
Treatment with betablokers is considered to be a standard for all patients. 
a Maximum heart rate during activity <100 lpm (adults) and up to 110 lpm (children) with 
betablockers. 
b If there is usual sport practice, it is suitable to follow-up the growth rate of the aortic root 
by a transthoracic echocardiogram each six months. 
The presence of significant aortic regurgitation with aortic root dilatation makes inadvisable 
any type of sports practice. 
Table 9. Recommendations for the physical activity in Marfan's syndrome  
In what concerns the aspects of the surgical techniques, the Bono and Bentall procedure has 
been considered the gold standard for the treatment of these patients. It consists in replacing 
the root and the aortic valve with a composite graft by a dacron vascular graft (rectum or 
with morphology that imitates to Valsalva's sinus) and a prosthetic valve; the coronary 
arteries have to be reimplanted into the vascular graft. Diverse technical variations 
(inclusion vs interposition, button technique, Cabrol modification or Svensson) have emerged 
over the years trying to reduce the early complications (bleeding, coronary occlusion) and 
the late ones (anastomotic pseudoaneurysms) of the same one, being the most used 
nowadays the Bono-Bentall by interposition with anastomosis of the coronary arteries in 
tablets (button technique). In young patients, mechanical prosthetic valves are the most used, 
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whereas in those of major age or with contraindications for anticoagulation, biological 
valves are usually used. 
 
Class I recommendations, level of evidence C 
External diameter of proximal aorta ≥ 50 mm 
External diameter <50mm with any of the following risk factors: 
 Familial history of dissection or aortic rupture 
 Rapid progression of the aortic diameter (> 5 mm/year) 
 Significant aortic regurgitation (moderate or major) 
Class IIa recommendations, level of evidence C
In women with MFS who wish to get pregnancy, it looks reasonable the aortic root and 
ascending aorta replacement when the diameter is > 40 mm 
Aortic surgery will be recommended when the quotient of the proximal aortic 
maximum area (in cm2) divided by the stature in meters is superior to 10, since the 
smallest patients and up to 15% of the MFS patients have aortic dissection with 
diameters <50 mm 
Table 10. Criteria for the elective surgery of the aorta proximal in adults with MFS 
The immediate and long-term results of this technique are very good, and the rates of the 
long-term survival are similar to those of the general population. Nevertheless, the 
results deteriorate considerably when the surgery is realized in an emergent form in the 
context of an aortic dissection. The long-term morbidity of these patients is in relation 
with the fact of being carriers of a valve prosthesis. This is the reason why in the last 
years some techniques have emerged to try to preserve the native aortic valve, which is 
re-implanted to the dacron vascular graft. They are the valve preserving techniques or 
valve-sparing, basically with two variants, the reimplantation technique or David procedure 
and the remodeling technique or Yacoub's surgery. In both cases, the aortic root is cut just 
above the aortic valve annulus and the coronary ostia; the diseased portion of aorta is 
removed and a collagen-coated polyester graft is used. In the modified David procedure, 
the sutures are placed just below the aortic valve, around the left ventricular outflow 
tract, and these sutures are then tied around a Hegar´s dilator to shape the bottom 
portion of the aort graft similar to a natural aortic root. Next, the valve is resuspendided 
within the graft, the aortic valve may be repaired or remodeled, and small holes are 
produced in the aorta graft for the coronary ostia, which are re-attached through the 
small holes.  
In the Yacoub technique, the graft of dacron stands out imitating Valsalva's bosoms and 
the graft is sutured to the remnants of aortic fabric that stay close to the insertion of the 
veils. 
David's technique is the one that more followers has inside the surgical community since 
theoretically it  stabilizes better the valvular ring, though there are surgeons who praise the 
use of Yacoub's technique associated with maneuvers of stabilization to annul (anuloplastias 
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with suture or with external rings), since this skill preserves better the functionality of the 
aortic root. 
Those valve sparing methods can be realized either if the aortic valve is competent in 
the moment of the intervention or whenit is not, though in the latter case, specially if 
the regurgitación is very ancient, it maybe not possible to preserve the valve. This owes 
to the intense elongation that the leaflets can present, with very thin and friable tissue 
even with big fenestrations, on having been submitted to a great mechanical tension for 
a long time. 
The immediate results of these procedures are similar to those of Bentall's surgery, though 
they are technically challenging, so they are used only in reference centres [9]. The long-term 
results also are excellent, remaining the patients free of significant degrees of aortic valve 
regurgitation and reoperation greater to 90% at 10 years [10]. 
Given these good long-term results, in many centers the valve sparing surgeries have turned 
into the new gold standard for the patients with Marfan syndrome.  
2.8. Elective surgery of the descending aorta 
Though the elective surgery of the descending aorta is nowadays a safe procedure, the risk 
of paraplegia is still present (that should be lower than 5%) depending on the group 
experience, on the extension of the aortic segment to be replaced and on the spinal cord 
protection. Since the operative risk increases in the emergency cases (dissection or rupture), 
and given the limitation for the use of stents in these patients, it is recommended the 
prophylactic replacement of the aortic segment when the diameter is > 55mm (class I 
recommendation, level of evidence C). 
2.9. Treatment of the acute aortic complications 
The treatment of the acute aortic complications in patients with MFS includes the 
management of the type A and B ascending aortic dissection (table 11).  
Type A ascending aortic dissection  
Given that the unpredictable nature of the aortic dissection in the MFS, it is necessary to 
educate the patients on the symptoms of the acute aortic dissection. As in the general 
population, the type A aortic dissection in the MFS is a emergency surgery emergency in 
which there must be replaced the sinus and the sufficient extension of the ascending 
aorta. 
Type B descending aortic dissection 
The type B aortic dissection represents approximately 10% of the acute aortic dissections in 
the MFS. Like in other patients, the medical management is initially recommended, except 
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complications or lack of response, in which case, the surgery must be considered. The 
routine accomplishment of CT or MRI is recommended if the descending aorta is large or if 
it has been dissected after the repair of a type A dissection. In the type B chronic aortic 
dissection it is recommended the open surgery when, in the absence of high comorbidity, 
the aorta diameter is >55mm. 
 
 
Type A ascending aortic 
dissection  
Emergency surgerya
Type B descending aortic 
dissection 
Initial management: medial treatmenta  
Type B acute aortic 
diseection 
Surgery indicated ifb: 
 Mesenteric ischaemia, limbs or branches of the 
abdominal aorta 
 Progression of the dissection 
 Accelerated rate of the aortic diameter 
 Inability to control the symptoms (pain...) or PA 
Type B chronic aortic 
dissection 
In the absence of a elevated comorbidity, open surgery if 
the diameter > 55 mma 
Endovascular therapy The stents of the descending aorta are not indicated in 
patients with MFS, except in those cases with conditions 
prohibiting the conventional open surgery 
a Class I recommendation, level of evidence B. 
b Later management: betablockers, additional medication if it is necessary for the control 
of the arterial pressure, and follow-up with MRI or CT according to the symptoms, the 
diameter and the aortic growth rate. 
 
Table 11. Treatment of the aortic complications in Marfan's syndrome 
2.10. Therapy endovascular with stents 
Though the experience with endoprosthesis in the type B acute or chronic aortic 
dissection in the MFS is limited, it has been observed that in spite of the correct 
implantation of the stent, with total thrombosis of the false light, the aorta continues 
expanding. This is the reason for which it is not recommended to use aortic stents in the 
MFS, except high risk for the conventional surgery. The pseudoaneurysms after aortic 
replacement can be an exception when it is possible to fix to the previous graft the stent 
to seal the point of entry of the false aneurysm as an alternative to the surgical 
reintervention (table 12). 
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Before discharge postsurgery CT or RMIa: complete aorta
At 6 months CT or RMI: to value diameters 
 Stable: annual 
 Progression: every 6 months 
Anually Throughout life, except unstabilization 
Appearance of complications  CT or RMI at 1,3, 6 and 12 months 
If later stable: annual 
 Class IIa recommendation, level of evidence C. 
 a The aorta must be valued in its entirety, not only the ascending portion, since a great 
proportion (almost a third) of the aortic events that compromise the distal aorta happen 
during the follow-up of these patients. 
Table 12. Follow-up after aortic surgery in Marfan's syndrome 
2.11. Recommendations after the aortic intervention  
in the MFS 
After the aortic repair, the grafts, relatively rigid, transmit tension towards contiguous 
territories, as the coronary arteries, the aortic arch and principal trunks, and the descending 
aorta, predisposing to the late development of aneurysms and dissection. These patients 
must support the treatment with betablockers and they must be followed by means  
of imaging techniques throughout life, restricting the irradiation for CT when possible  
(table 12). 
2.12. Surgery of the valvular mitral prolapse  
in the SM 
The mitral and tricuspid affectations constitute the most frequents cardiac finding in the 
MFS, though the tricuspid rarely has repercussion. The alterations of the mitral connective 
tissue carry to the growth in a myxoid aspect, with high content of air in its interior, 
though the histology and the morphology of the mitral valve in patients with MFS are 
different from the classic myxoid valve disease. In the MFS the leaflets, though thicker 
than normal, they are longer and thinner than the mixoides ones and with minor 
celularity.  
Patients with MFS present more frequently affectation of both leaflets or the anterior one, 
which, together with the laxity of the valvular tissue, makes more frequent the prevalency of 
mitral prolapse in patients with MFS compared with the healthy population (50-80% 
opposite to 2,4%). In these patients the prolapse can produce moderate mitral regurgitation 
or major up to 25 % of the cases. It is also typical the trend to the early calcification of the 
mitral ring, which constitutes a minor diagnostic criteria.  
In the most serious forms of the MFS, which begin in the first years of life, the mitral 
affectation can cause cardiac heart failure and pulmonary hypertension, with very 
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unfavorable surgical results in younger than 2 years old, being an important reason for 
mortality in children with MFS. In teenagers and adults the surgical repair of the severe 
mitral severe regurgitation is associated with a high events free survival.  
The mitral isolated surgery is infrequent, and in the majority of the occasions we carry out 
combined conservative procedures on the aorta and the mitral valves to avoid the 
anticoagulation therapy.  
The extensive calcification of the mitral ring is the main contraindication for the mitral 
repair in the MFS. It is important to insist that not repair severe mitral regurgitation, 
concerns adversely the aortic hemodynamic stress and the ventricular function in the 
MFS. 
In a similar way to the case of the aortic valve, the classic method used in patients with 
severe mitral regurgitation is the valve replacement, usually with mechanical prosthesis. 
Nevertheless, and given the high morbidity that these can produce over the years because of 
the thromboembolic and infectious events, the conservative mitral valve techniques are the 
gold standard of the mitral surgery, with long-term results similar to the ones obtained in 
patients without Marfan's syndrome. 
Before this type of valves, the surgeon must use the whole available technical equipment 
and devices, being in an extensively use the PTFE's neocordae, and always associating 
annuloplasty rings, preferably rigidly or semi rigid. In occasions, it is used the double orifice 
technique, described by Alfieri, less demanding technically, though the anatomical repair 
methods are the ones preferred. 
The immediate and long-term results are very good, with events free survival  
and reintervention free survival of 95 % at 10 years, specially when the early surgery is 
indicated.  
2.13. Other cardiovascular manifestations of the SM 
The expansion of the trunk of the pulmonary artery is less frequent than the aortic one, and 
rarely it causes dissection. In the MFS it is possible to have alterations in the atrioventricular 
conduction and in the ventricular repolarization (long QT, ST alterations and U waves), that 
might be associated with ventricular arrhythmias, but it is not clear if these changes are 
secondary to a primary myocardiopathie or to ventricular dilatation owed to the evolved 
regurgitations. 
3. Conclusion 
The diagnosis of Marfan syndrome is inevitably complex, due to the high variability of 
presentation of affected individuals, the dependence of the age in many clinical 
manifestations, the absence of gold standards diagnostic tests, and the wide differential 
diagnosis. The new Marfan syndrome diagnostic criteria are intended to facilitate a 
 
Marfan Syndrome – Advances in Diagnosis and Management 451 
correct and early identification by professionals and improve the prognosis of these 
patients. 
In last decades there have been significant changes in the prognosis of the Marfan 
syndrome. Cardiovascular management of these patients is based on three pillars aimed to 
increase hope and quality of life: stratification of risk, medical treatment and prophylactic 
aortic surgery. 
Imaging techniques contribute to establish the risk of these patients and select better cases 
and the most appropriate time for the indication of elective surgery. 
All patients should be treated early, at least with beta-blockers. Meanwhile, it will continue 
to evaluate new therapies aimed at stopping or even reversing the pathological changes 
associated with the disease. 
More and more patients with Marfan syndrome will achieve more advanced stages of life, 
and this will mean new challenges. It will be tested the acquired knowledge and teamwork 
from specialized multidisciplinary units will be essential. 
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